CELEX: 62015TA0235
Language: en
Date: 2018-02-05 00:00:00
Title: Case T-235/15: Judgment of the General Court of 5 February 2018 — Pari Pharma v EMA (Access to documents — Regulation (EC) No 1049/2001 — Documents held by the EMA and submitted in the context of the application for marketing authorisation for the medicinal product Vantobra — Decision to grant a third party access to the documents — Exception relating to the protection of commercial interests — No general presumption of confidentiality)

19.3.2018   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 104/26
            
         Judgment of the General Court of 5 February 2018 — Pari Pharma v EMA
   (Case T-235/15) (1)
   
   ((Access to documents - Regulation (EC) No 1049/2001 - Documents held by the EMA and submitted in the context of the application for marketing authorisation for the medicinal product Vantobra - Decision to grant a third party access to the documents - Exception relating to the protection of commercial interests - No general presumption of confidentiality))
   (2018/C 104/33)
   Language of the case: English
   
      Parties
   
   
      Applicant: Pari Pharma GmbH (Starnberg, Germany) (represented by: M. Epping and W. Rehmann, lawyers)
   
      Defendant: European Medicines Agency (EMA) (represented by: T. Jabłoński, A. Rusanov, S. Marino, A. Spina and N. Rampal Olmedo, acting as Agents)
   
      Interveners in support of the defendant: French Republic (represented by: D. Colas and J. Traband, acting as Agents) and Novartis Europharm Ltd (Camberley, United Kingdom) (represented by: C. Schoonderbeek, lawyer)
   
      Re:
   
   Action under Article 263 TFEU for the annulment of Decision EMA/271043/2015 of the EMA of 24 April 2015, granting to a third party, pursuant to Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to European Parliament, Council and Commission documents (OJ 2001 L 145, p. 43), access to documents containing information submitted in the context of an application for marketing authorisation for the medicinal product Vantobra.
   
      Operative part of the judgment
   
   The Court:
   
               1.
            
            
               Dismisses the action;
            
         
               2.
            
            
               Orders Pari Pharma GmbH to bear its own costs and to pay those incurred by the European Medicines Agency (EMA), including those relating to the application for interim measures;
            
         
               3.
            
            
               Orders the French Republic to bear its own costs;
            
         
               4.
            
            
               Orders Novartis Europharm Ltd to bear its own costs.
            
         
      (1)  OJ C 221, 6.7.2015.